Page last updated: 2024-12-05

veratridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Veratridine: A benzoate-cevane found in VERATRUM and Schoenocaulon. It activates SODIUM CHANNELS to stay open longer than normal. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6280
CHEMBL ID439496
CHEBI ID28051
SCHEMBL ID50074
MeSH IDM0022610
PubMed CID11614496
CHEMBL ID4296897
SCHEMBL ID10324299
MeSH IDM0022610

Synonyms (62)

Synonym
BRD-K60923938-001-02-8
gtpl2626
NCI60_041647
BSPBIO_001515
brn 0078875
veratrine (amorphous) (van)
einecs 200-758-4
4,9-epoxycevane-3,4,12,14,16,17,20-heptol 3-(3,4-dimethoxybenzoate)
cevane-3,4,12,14,16,17,20-heptol, 4,9-epoxy-, 3-(3,4-dimethoxybenzoate), (3beta,4alpha,16beta)-
nsc 7524
4,9-epoxycevane-3beta,4alpha,12,14,16beta,17,20-heptol 3-veratrate
hsdb 4078
cevane-3-beta,4-alpha,12,14,16-beta,17,20-heptol, 4,9-epoxy-, 3-(3,4-dimethoxybenzoate)
NCGC00163144-03
4beta,12,14,16beta,17,20-hexahydroxy-4alpha,9-epoxycevan-3beta-yl 3,4-dimethoxybenzoate
veratridin
CHEBI:28051 ,
HMS1989L17
1,2,4-triazolo[4,3-a]pyridin-3-ol
HMS1791L17
5-21-13-00709 (beilstein handbook reference)
unii-m4bnp1kr7w
m4bnp1kr7w ,
4,9-epoxycevane-3-beta,4-beta,12,14,16-beta,17,20-heptol 3-veratrate
niosh/fl5630000
cevane-3-beta,4-beta,12,14,16-beta,17,20-heptol, 4,9-epoxy-, 3-veratrate
FL56300000 ,
3-veratroylveracevin
c36h51no11
(3.beta.,4.beta.,16.beta.)-4,12,14,16,17,20-hexahydroxy-4,9-epoxycevan-3yl 3,4-dimethoxybenzoate
veratridine [hsdb]
(3.beta.,4.alpha.,16.beta.)-4,9-epoxycevane-3,4,12,14,16,17,20-heptol 3-(3,4-dimethoxybenzoate)
veratridine [mi]
CCG-208285
SCHEMBL50074
CHEMBL439496
4?,9-epoxy-3?-veratroyloxy-5?-cevan-4?,12,14,16?,17,20-hexaol
4alpha,9-epoxy-3beta-veratroyloxy-5beta-cevan-4beta, 12,14,16beta,17,20-hexaol
HB1006
AKOS024457334
HMS3402L17
bdbm50214776
cevane-3,4,12,14,16,17,20-heptol, 4,9-epoxy-, 3-(3,4-dimethoxybenzoate), (3?,4?,16?)-; veratridine (6ci,7ci,8ci); 3-veratroylveracevine; nsc 7524; veracevine, veratrate
Q721202
CS-0029015
MS-31063
HY-N6691
[(1r,2s,6s,9s,10r,11s,12s,14r,15s,18s,19s,22s,23s,25r)-1,10,11,12,14,23-hexahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.02,11.04,9.015,25.018,23.019,25]hexacosan-22-yl] 3,4-dimethoxybenzoate
nsc7524 ,
3-veratroylveracevine
nsc-7524
mls000736575 ,
wln: t j6 h6 e6 d5665/tc& 3atu c& on tx c&otj eq gq hq iq i1 m1 rq u1 a&ovr co1 do1& b&q
veratrine (amorphous)
cevane-3,12,14,16,17,20-heptol, 4,9-epoxy-, 3-(3,4-dimethoxybenzoate), (3.beta.,4.alpha.,16.beta.)-
4,4,12,14,16,17,20-heptol 3-(3,4-dimethoxybenzoate)
71-62-5
veratridine
SCHEMBL10324299
CHEMBL4296897
[(1r,2s,6s,9s,10r,11s,12s,14r,15s,19s,23s,25r)-1,10,11,12,14,23-hexahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.02,11.04,9.015,25.018,23.019,25]hexacosan-22-yl] 3,4-dimethoxybenzoate
[(1r,2s,6s,9s,10r,11s,12s,14r,15s,18s,19s,22s,23r,25r)-1,10,11,12,14,23-hexahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.02,11.04,9.015,25.018,23.019,25]hexacosan-22-yl] 3,4-dimethoxybenzoate

Research Excerpts

Toxicity

Veratridine (100 microM) or ouabain alone were not toxic to the cells. Veratridin was also toxic to 21DIV neurons which are independent of NGF for survival.

ExcerptReferenceRelevance
"It has long been proposed that the excitatory and toxic properties of acidic amino acid receptor agonists are linked."( Amino acid neurotoxicity: relationship to neuronal depolarization in rat cerebellar slices.
Garthwaite, G; Garthwaite, J; Hajós, F, 1986
)
0.27
" Veratridine was also toxic to 21DIV neurons which are independent of NGF for survival."( Alteration of veratridine neurotoxicity in sympathetic neurons during development in vitro.
Koike, T; Ninomiya, T, 2000
)
0.31
" Ara C was found to be toxic to cerebellar cells after potassium withdrawal at concentrations standardly used in culturing these cells (10 microM)."( High extracellular potassium protects against the toxicity of cytosine arabinoside but is not required for the survival of cerebellar granule cells in vitro.
Brown, DR; Daniels, M, 2002
)
0.31
" Veratridine (100 microM) or ouabain alone (500 microM) were not toxic to the cells."( A novel toxicity-based assay for the identification of modulators of voltage-gated Na+ channels.
Weiser, T, 2004
)
0.32
" The toxic effects of brevetoxins are believed to be due to the activation of voltage-sensitive sodium channels in cell membranes."( A new cytotoxicity assay for brevetoxins using fluorescence microscopy.
Bourdelais, AJ; Elliott, EA; McCall, JR, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."( Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" Log dose-response curves of the adrenal cells for ACTH and of the pituitary cell-adrenal cell system for CRF were linear over the ranges used."( A superfusion system technique for the study of the sites of action of glucocorticoids in the rat hypothalamus-pituitary-adrenal system in vitro. II. Hypothalamus-pituitary cell-adrenal cell superfusion.
Mulder, GH; Smelik, PG; Vermes, I, 1977
)
0.26
" The potentiated levels of [3H]IP were strongly dependent on K+ concentration and displayed a dose-response relationship with the agonist."( Potentiation of [3H]inositol phosphate formation by receptor activation and membrane depolarization in brain cortical slices (I).
Atlas, D; Diamant, S, 1989
)
0.28
" The dose-response curve of the GABA-evoked catecholamine release was shifted to the left by midazolam without affecting the maximal response to GABA."( Benzodiazepines facilitate the stimulatory action of gamma-aminobutyric acid (GABA) on basal and veratridine-evoked catecholamine release from cultured bovine adrenal chromaffin cells.
Dohi, T; Kitayama, S; Morita, K; Tsujimoto, A,
)
0.13
" Dose-response curves for inhibition of component T by all three agents were monophasic."( Potassium channels in isolated presynaptic nerve terminals from rat brain.
Bartschat, DK; Blaustein, MP, 1985
)
0.27
" The dose-response relations for exogenous noradrenaline measured in the absence or presence of 50 microM amiloride indicated that the drug acted as a reversible competitive alpha-adrenergic antagonist."( Amiloride acts as an alpha-adrenergic antagonist in the isolated rat tail artery.
Palatý, V, 1986
)
0.27
" We found that excitatory amino acid agonists evoked somatostatin release in the following order of potency: quisqualate greater than glutamate = N-methyl-D-aspartate (NMDA) greater than kainate, as calculated from the dose-response curves."( Glutamate stimulates somatostatin release from diencephalic neurons in primary culture.
Astier, H; Tapia-Arancibia, L, 1988
)
0.27
" A dose-response relationship between inhibition of alpha-MSH secretion and the concentration of Leu-enkephalin, with ED50 approximately 10(-9) M, was observed."( Modulation by Leu-enkephalin of peptide release from perifused neurointermediate pituitary. II. Inhibition of calcium-mediated secretion of alpha-MSH and beta-endorphin.
Al Zein, M; Koch, B; Lutz-Bucher, B, 1986
)
0.27
" Dose-response relationships showed a close association between seizure activity (measured by EEG) and extracellular Ca2+ changes in the injected area."( Quinolinic acid-induced seizures, but not nerve cell death, are associated with extracellular Ca2+ decrease assessed in the hippocampus by brain dialysis.
Angelico, P; Samanin, R; Stasi, MA; Vezzani, A; Wu, HQ, 1988
)
0.27
" The dose-response curves for noradrenaline, acetylcholine and KCl was not affected by GTX II (2 X 10(-7) to 10(-6) M)."( Presynaptic inhibitory effect of geographutoxin II, a new peptide toxin from Conus geographus venom, in the guinea-pig vas deferens.
Kobayashi, J; Nakamura, H; Ohizumi, Y, 1986
)
0.27
" accommodation was enhanced) at the anesthetic dosage level."( A comparison of the effects of pentobarbital and diphenylhydantoin on the GABA sensitivity and excitability of adult sensory ganglion cells.
Connors, BW, 1981
)
0.26
"6 Dose-response curves for the rate of drug-induced relaxation of tonic contractures produced in hypertonic 42."( The calcium antagonistic effects of cyproheptadine on contraction, membrane electrical events and calcium influx in the guinea-pig taenia coli.
Lowe, DA; Matthews, EK; Richardson, BP, 1981
)
0.26
" Dose-response curves for VIP and enkephalin release by the above secretagogues were similar but not identical."( Primary cultures of bovine chromaffin cells synthesize and secrete vasoactive intestinal polypeptide (VIP).
Eiden, LE; Eskay, RL; Hotchkiss, AJ; Pollard, H; Scott, J, 1983
)
0.27
" Therefore, safinamide may be used in PD to reduce l-dopa dosage and also represents a valuable therapeutic drug to test disease-modifying potential."( Safinamide: from molecular targets to a new anti-Parkinson drug.
Caccia, C; Calabresi, M; Curatolo, L; Faravelli, L; Fariello, RG; Maestroni, S; Maj, R; Salvati, P, 2006
)
0.33
"The measured data and simulations for pharmacologically unstimulated contraction resembled findings in native human heart tissue, while the pharmacological dose-response curves were highly accurate and consistent with reference data."( Mechano-Pharmacological Characterization of Cardiomyocytes Derived from Human Induced Pluripotent Stem Cells.
Artmann, AT; Artmann, GM; Bayer, R; Epple, M; Frotscher, R; Goßmann, M; Linder, P; Neumann, S; Staat, M, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
sodium channel modulatornull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
steroidAny of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene which is a triterpene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bifunctional purine biosynthesis protein ATICHomo sapiens (human)IC50 (µMol)231.30000.01000.26000.7000AID282344
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
brainstem developmentBifunctional purine biosynthesis protein ATICHomo sapiens (human)
nucleobase-containing compound metabolic processBifunctional purine biosynthesis protein ATICHomo sapiens (human)
GMP biosynthetic processBifunctional purine biosynthesis protein ATICHomo sapiens (human)
'de novo' IMP biosynthetic processBifunctional purine biosynthesis protein ATICHomo sapiens (human)
response to inorganic substanceBifunctional purine biosynthesis protein ATICHomo sapiens (human)
cerebellum developmentBifunctional purine biosynthesis protein ATICHomo sapiens (human)
cerebral cortex developmentBifunctional purine biosynthesis protein ATICHomo sapiens (human)
animal organ regenerationBifunctional purine biosynthesis protein ATICHomo sapiens (human)
'de novo' AMP biosynthetic processBifunctional purine biosynthesis protein ATICHomo sapiens (human)
dihydrofolate metabolic processBifunctional purine biosynthesis protein ATICHomo sapiens (human)
tetrahydrofolate biosynthetic processBifunctional purine biosynthesis protein ATICHomo sapiens (human)
'de novo' XMP biosynthetic processBifunctional purine biosynthesis protein ATICHomo sapiens (human)
cellular response to interleukin-7Bifunctional purine biosynthesis protein ATICHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
IMP cyclohydrolase activityBifunctional purine biosynthesis protein ATICHomo sapiens (human)
protein homodimerization activityBifunctional purine biosynthesis protein ATICHomo sapiens (human)
cadherin bindingBifunctional purine biosynthesis protein ATICHomo sapiens (human)
phosphoribosylaminoimidazolecarboxamide formyltransferase activityBifunctional purine biosynthesis protein ATICHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytosolBifunctional purine biosynthesis protein ATICHomo sapiens (human)
plasma membraneBifunctional purine biosynthesis protein ATICHomo sapiens (human)
membraneBifunctional purine biosynthesis protein ATICHomo sapiens (human)
extracellular exosomeBifunctional purine biosynthesis protein ATICHomo sapiens (human)
cytosolBifunctional purine biosynthesis protein ATICHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1246046Toxicity in mouse2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications.
AID752203Binding affinity to sodium channel site 2 (unknown origin) by radioligand displacement assay2013Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1597294Displacement of [3H] batrachotoxinin from rat sodium channel site 2 measured after 60 mins by scintillation counter method
AID340273Inhibition of sodium channel site 22008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID751839Binding affinity to sodium channel site 2 (unknown origin) by radioligand displacement assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
AID660294Binding affinity to transmembrane model peptide-2 of domain 4 segment 6 of rat skeletal muscle Nav1.4 by Marquardt and Levenberg algorithm analysis2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Solution NMR analysis of the binding mechanism of DIVS6 model peptides of voltage-gated sodium channels and the lipid soluble alkaloid veratridine.
AID401520Displacement of radioligand from rat sodium channel batrachotoxin binding site by liquid scintillation spectrometry1997Journal of natural products, Apr, Volume: 60, Issue:4
Perhydrogenation of tabersonine, ans Aspidiosperma indole alkaloid.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID346468Displacement of radiolabeled veratridine from sodium channel site 22008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID282344Inhibition of human AICAR Tfase2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identify novel nonfolate inhibitors.
AID323973Displacement of [3H]batrachotoxinin from sodium channel site 2 at 10 uM relative to veratridine2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Aryl azoles with neuroprotective activity--parallel synthesis and attempts at target identification.
AID1285671Displacement of [125I]batrachotoxin from rat cerebral cortex Sodium channel site 22016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID660292Toxicity in ip dosed mouse2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Solution NMR analysis of the binding mechanism of DIVS6 model peptides of voltage-gated sodium channels and the lipid soluble alkaloid veratridine.
AID566351Inhibition of rat Na+ channel site 22010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID660293Binding affinity to transmembrane model peptide-1 of domain 4 segment 6 of rat skeletal muscle Nav1.4 by Marquardt and Levenberg algorithm analysis2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Solution NMR analysis of the binding mechanism of DIVS6 model peptides of voltage-gated sodium channels and the lipid soluble alkaloid veratridine.
AID1346772Rat Nav1.5 (Voltage-gated sodium channels)1990Molecular pharmacology, Feb, Volume: 37, Issue:2
Sodium channel comodification with full activator reveals veratridine reaction dynamics.
AID1346781Rat Nav1.4 (Voltage-gated sodium channels)1998Proceedings of the National Academy of Sciences of the United States of America, Mar-03, Volume: 95, Issue:5
Point mutations in segment I-S6 render voltage-gated Na+ channels resistant to batrachotoxin.
AID1346731Rat Nav1.2 (Voltage-gated sodium channels)1981The Journal of biological chemistry, Sep-10, Volume: 256, Issue:17
Binding of batrachotoxinin A 20-alpha-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles.
AID1346760Rat Nav1.8 (Voltage-gated sodium channels)2008Pflugers Archiv : European journal of physiology, Feb, Volume: 455, Issue:5
A comparison of the effects of veratridine on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels in isolated rat dorsal root ganglion neurons.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,739)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990810 (46.58)18.7374
1990's554 (31.86)18.2507
2000's262 (15.07)29.6817
2010's100 (5.75)24.3611
2020's13 (0.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.97 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index58.03 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews2 (10.00%)6.00%
Reviews22 (1.25%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies2 (0.11%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other18 (90.00%)84.16%
Other1,731 (98.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]